Last updated: 2026-09-16 13:20:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Passage Bio, Inc. (PASG) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $4.80, with a market capitalisation of $15.64M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.29 to $20.00. This page covers its latest market performance, valuation, price trends and company information.
$15.64M | |
$4.84 | |
$764.60 | |
$3.29 | |
$4.77 | |
267.00 | |
65.75K | |
-- | |
$20.00 | |
$3.29 | |
-- | |
-- |
Passage Bio, Inc. (PASG) is trading at $4.80 in pre-market trading as of 2026-09-16 12:17:00, up 0.61% ($0.03) from the previous close of $4.77
Pre-market trading shows how investors are pricing PASG before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Passage Bio, Inc. (PASG) moved from $4.65 to $4.80, representing a gain of 3.20% ($0.15).
The stock traded between $4.63 and $5.36 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 41.81 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 9.0%
PASG is currently trading at $4.80, placing it 9.0% of the way from its 52-week low of $3.29 to its 52-week high of $20.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 24 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Passage Bio, Inc. (PASG) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.